CVRx reported third-quarter 2026 total revenue of $13.8 million, a 6% decline from the prior year period, driven by lower sales force productivity and payer challenges. The company posted a net loss of $14.2 million, or $0.52 per share, compared to a $12.9 million loss in Q3 2025. Gross margin remained steady at 87%, while R&D expenses decreased by 16% and SG&A increased slightly by 2%. The firm lowered its full-year 2026 revenue guidance to between $56.0 million and $57.0 million, down from the previous range of $58.0 million to $60.0 million. Additionally, John Landry was appointed as Chief Financial Officer effective November 6, 2026, succeeding Jared Oasheim. CVRx is a commercial-stage medical device company focused on developing and commercializing neuromodulation solutions for patients with cardiovascular diseases.
